[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.248.103. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    What's your (pill) bottle?
    Jack J. Chen, PharmD, FCCP, BCPS, CGP | School of Pharmacy, Loma Linda University


    Pharmacists are aware of medication adherence as well as pharmaceutical and clinical outcome issues surrounding generic drugs. Some pharmacists do exercise professional discretion and judgment when refilling medications with a different NDC. Anecdotally, some pharmacists will make every effort to maintain NDC consistency among refills for antiepileptic drugs and other drug classes.

    It is known that patients on daily medications for chronic illnesses are aware of changes in pill appearance [1] and Kesselheim et al. have demonstrated a posteriori that such changes are associated with risk of medication impersistence (i.e, interrupted adherence to maintenance therapy) among patients taking antiepileptic drugs [2]. The authors emphasize differences in appearance between brand-name drugs and generic counterparts. However, it is unclear what percentage of discordant cases were due to substitution of 1) brand drug with a generic drug or 2) generic drug to another generic version. If a drug is available as a generic, patients will often be initiated on the generic drug and may never receive the brand drug.

    Based on the study methods (e.g., dates of data collection, antiepileptic drugs), I surmise that changes in pill appearance due to the latter scenario was likely dominant but would like to the authors to clarify. This is important from a pharmaceutical industry and regulatory perspective since “trade dress” jurisprudence, a form of exclusivity, is not likely to be claimed by generic drug manufacturers. 

    One step towards reducing variation in generic drug appearance and the potential number of color and shape arrays would involve policy changes that standardize the pill appearance among all marketed generic versions. Therefore, for each dose of a brand drug, there could, in theory, be only one color and shape for the corresponding generic drug and dose, regardless of the generic drug manufacturer. It is also important to note the trend towards use of mail order refill services [3] and that such services appear to be associated with better medication adherence.[4] It is unclear whether Kesselheim et al. controlled for this variable among concordant and discordant cases. For the patients who pick-up their refills in a pharmacy, Kesselheim et al. suggest that “At pharmacies, the ability to alert consumers when pill features have changed may require adaptations to information technology systems.”[2] In fact, such systems are already in place. Pharmacies have software that provide an on-screen alert when there is an NDC change upon medication refill. Depending on the software, the alert will generate either an auxiliary label indicating the potential change in pill appearance and/or similar text on the medication guide. If not, pharmacists may attach an auxiliary label (often referred to as the “green sticker) indicating a potential change in pill appearance. Even in the absence of such systems, pharmacists and pharmacy technicians may use a “show and tell” approach when dispensing refills. This allows the patient an opportunity to visually detect if pill appearance has changed and to seek clarification. However, caregivers may pick-up the refilled medication; anecdotally, in such situations, the new information may not reach the patient. 

    I also believe there is variability in consistency of new information being communicated to patients and agree with Kesselheim et al. that “pharmacists might take greater care to alert patients when changes in suppliers lead to new pill characteristics.”[2]

    Communication of new information is a team effort and since the act of alerting patients of changes in pill appearance is non-discretionary, pharmacists should remind pharmacy technicians, clerks and pharmacy cashiers to also verbally inform patients of potential changes in pill appearance. 



    References

    1. Toverud EL, Røise AK, Hogstad G, Wabø I. Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences. Eur J Clin Pharmacol. 2011;67(1):33-38.

    2. Kesselheim AS, Misono AS, Shrank WH, et al. Variations in pill appearance of antiepileptic drugs and risk of non-adherence. JAMA Intern Med. 2013;173(3):202-208.

    3. http://www.nytimes.com/2011/03/04/business/04drug.html?_r=04. Sharma KP, Taylor TN. Pharmacy effect on adherence to antidiabetic medications. Med Care. 2012;50(8):685-691.







    CONFLICT OF INTEREST: None Reported
    READ MORE
    Original Investigation
    Feb 11, 2013

    Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence

    Author Affiliations

    Author Affiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Kesselheim, Misono, Shrank, Greene, Avorn, and Choudhry and Mr Doherty); Department of History and Science, Harvard University, Cambridge, Massachusetts (Dr Greene); and the Centers for Medicare and Medicaid Services, Baltimore, Maryland (Dr Shrank).

    JAMA Intern Med. 2013;173(3):202-208. doi:10.1001/2013.jamainternmed.997
    Abstract

    Background Generic prescription drugs are bioequivalent to brand-name versions but may not have consistent color or shape, which can cause confusion and lead to interruptions in medication use. We sought to determine whether switching among different-appearing antiepileptic drugs (AEDs) is associated with increased rates of medication nonpersistence, which can have serious medical, financial, and social consequences.

    Methods We designed a nested case-control study of commercially insured patients in the United States who initiated an AED. Cases were patients who became nonpersistent, defined as failure to fill a prescription within 5 days of the elapsed days supplied. Controls had no delay in refilling and were matched by sex, age, number of refills, and the presence of a seizure disorder diagnosis. We evaluated the 2 refills preceding nonpersistence and determined whether pill color and/or shape matched (“concordant”) or did not match (“discordant”). We compared the odds of discordance among cases and controls using multivariate conditional logistic regression, adjusting for baseline characteristics, and drug type. We repeated our analysis among patients with a seizure diagnosis.

    Results The AEDs dispensed had 37 colors and 4 shapes. A total of 11 472 patients with nonpersistence were linked to 50 050 controls. Color discordance preceded 136 cases (1.20%) but only 480 controls (0.97%) (adjusted odds ratio [OR], 1.27 [95% CI, 1.04-1.55]). Shape discordance preceded 18 cases (0.16%) and 54 controls (0.11%) (OR, 1.47 [95% CI, 0.85-2.54]). Within the seizure disorder diagnosis subgroup, the risk of nonpersistence after changes in pill color was also significantly elevated (OR, 1.53 [95%, CI 1.07-2.18]).

    Conclusions Changes in pill color significantly increase the odds of nonpersistence; this may have important clinical implications. Our study supports a reconsideration of current regulatory policy that permits wide variation in the appearance of bioequivalent drugs.

    ×